BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 31

• 

  COVID-19

  FDA assembles vaccine experts to update COVID-19 formulation

  The FDA will convene its vaccines advisory panel to discuss seasonal COVID-19 vaccines—a surprise move after Health Secretary and vaccine skeptic Robert F. Kennedy, Jr. overhauled a separate vaccine committee.

  May 27, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Vaccines

  Lilly just bought renowned regulator Peter Marks a pipeline to play with

  FDA veteran Peter Marks will now shape the future of Eli Lilly’s vaccines work after the buys of Curevo, LimmaTech Biologics and Vaccine Company for up to $3.8 billion total.

  May 27, 2026

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Immunology and inflammation

  Apogee investors riled by $1.3B royalty deal, as eczema drug matches Lilly’s Ebglyss

  Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.

  May 27, 2026

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  C-suite

  The top 5 highest paid pharma CEOs in 2025

  From Eli Lilly’s David Ricks to Pfizer’s Albert Bourla, the top five highest paid CEOs made a combined $157.8 million in 2025.

  May 27, 2026

   · 

  7 min read

   · 

  Annalee Armstrong
• 

  Rare diseases

  FDA accepts BridgeBio’s application for potential first limb-girdle muscular dystrophy drug

  The FDA’s priority review acceptance of BridgeBio’s BBP-418 is another step toward what William Blair previously dubbed a “diversified commercial portfolio.” It also adds to the rapidly building momentum in muscular dystrophy more broadly.

  May 27, 2026

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Career Advice

  Curse of the straight-A student

  The people most trusted to deliver are not always the ones invited to shape direction. Executive coach Angela Justice examines why the habits that build a career can eventually limit advancement.

  May 27, 2026

   · 

  4 min read

   · 

  Angela Justice
• 

  Insights

  Germany can produce biotech winners. Europe must back them better.

  Strong science and early support are not enough on their own. Europe needs more capital depth, cross-border investor backing and a lighter policy framework to keep companies scaling at home, according to two venture capitalists.

  May 27, 2026

   · 

  4 min read

   · 

  Jennifer C. Smith-Parker
• 

  Regulatory

  Makary’s reforms will live on at FDA even as leadership turns over

  Under the temporary reign of top food executive Kyle Diamantas, the FDA will sustain programs initiated by former Commissioner Marty Makary, including the Commissioner’s National Priority Voucher initiative.

  May 27, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Cancer

  Kura’s encouraging cancer drug data could unlock $2B market opportunity

  Nearly 80% of patients saw tumor shrinkage after being treated with Kura Oncology’s darlifarnib plus Bristol Myers Squibb’s Krazati, findings Mizuho analysts say could open up a $2 billion opportunity for the biotech.

  May 27, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Breast cancer

  AstraZeneca’s breast cancer pill hit with review delay after negative adcomm vote

  An FDA advisory committee recently voted against approving AstraZeneca’s oral SERD drug camizestrant for certain patients with advanced breast cancer. It is unclear when the new target action date for the drug will be.

  May 27, 2026

   · 

  4 min read

   · 

  Tristan Manalac